NYSTATIN - Kesin Pharma Corporation

Manufacturer
Kesin Pharma Corporation
Effective date
2026-06-30
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
daily-update
Hydrated at
2026-06-03 18:03:41

Label at a glance#

ProductNYSTATIN
Active ingredientNYSTATIN
Label structure12 sections

Indications and uses

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

Dosage and administration

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes). NOTE: L imited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective. CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth...

Storage and handling

SHAKE WELL BEFORE USE Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15° C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. AVOID FREEZING Pharmacists: Dispense in a tight, light-resistant container as defined in the USP. Distributed by: Kesin Pharma Oldsmar, FL 34677 Revised: 12/2025 PI-015B-V01

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei.
Structural formula:

image descriptionimage description

Nystatin Oral Suspension, for oral administration, is cherry/mint flavored, containing 100,000 USP Nystatin Units per mL. Inactive ingredients: cherry flavor, dibasic sodium phosphate heptahydrate, disodium edetate, glycerin, methylparaben, monobasic sodium phosphate monohydrate, peppermint oil, propylparaben, sodium benzoate, sodium hexametaphosphate, and sucrose.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Pharmacokinetics

PHARMACOKINETICS SECTION

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

MICROBIOLOGY SECTION

Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitroon repeated subculture in increasing levelso f nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects Category C

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

See DOSAGE AND ADMINISTRATION.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

To report SUSPECTED ADVERSE REACTIONS, contact Kesin Pharma at 1-833-537-4679 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see CLINICAL PHARMACOLOGY, Pharmacokinetics).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.

HOW SUPPLIED

HOW SUPPLIED SECTION

Nystatin Oral Suspension, USP 100,000 USP Nystatin Units per mL, is available as a cherry-mint flavored, yellow, ready-to-use suspension, supplied in the following oral dosage forms:

NDC 81033-015-60: 60 mL bottle with a 1 mL calibrated dropper

NDC 81033-015-16: 16 oz (473 mL) bottle

Rx Only

SHAKE WELL BEFORE USE

STORAGE AND HANDLING SECTION

SHAKE WELL BEFORE USE

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15° C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

AVOID FREEZING

Pharmacists: Dispense in a tight, light-resistant container as defined in the USP.

Distributed by:

Kesin Pharma

Oldsmar, FL 34677

Revised: 12/2025

PI-015B-V01

Kesin Pharma LogoKesin Pharma Logo

Nystatin 16 oz (473 mL)

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Rx Only

NDC 81033- 015-16

Nystatin Oral Suspension, USP

SHAKE WELL BEFORE USING

Nystatin 16 oz (473 mL) Bottle LabelNystatin 16 oz (473 mL) Bottle Label

Nystatin 60 mL Bottle and Carton Labels

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Rx Only

NDC 81033- 015-60

Nystatin Oral Suspension, USP

SHAKE WELL BEFORE USING

Nystatin 60 mL Bottle LabelNystatin 60 mL Bottle Label

Rx Only

NDC 81033- 015-60

Nystatin Oral Suspension, USP

SHAKE WELL BEFORE USING
(Includes safe cap dropper)

Nystatin 60 mL Bottle Carton LabelNystatin 60 mL Bottle Carton Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
312055nystatin 100,000 UNT/mL Oral SuspensionPSN1
312055nystatin 100000 UNT/ML Oral SuspensionSCD1
312055nystatin 100,000 UNT/ML Oral SuspensionSY1
312055nystatin 500,000 UNT per 5 ML Oral SuspensionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
NYSTATIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e29fe634-dc25-094c-c77f-5d09c3eceb3eProduct name520260107
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
e57b6340-9387-3f9a-7307-511c81791375Product name320221214
544f8e8d-6389-eeeb-9586-aa447c08dcc7Product name520210614
1629e00f-54fb-4a43-8306-b58442b23902Product name920200430
854ec07b-1cd7-a5db-235a-7aa24d3cf97aProduct name320180628
19b9f4c1-15e9-edcc-4c16-f01ecfb5c549Product name120140508
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
81033-015-01ML - Milliliter81033-0152cfb8a81-2eb0-4024-8476-284f8d06333612026-03-17
81033-015-05ML - Milliliter81033-01549867bf3-a8d3-4975-bb87-7df54876759212026-03-17
81033-015-54ML - Milliliter81033-01524ab3546-05de-4da6-a3a5-dadae4b1265b12026-03-17
85742-013-10ML - Milliliter85742-01306ea4c79-8f02-4af6-8b21-1b9ff937980b12025-12-16
85742-013-11ML - Milliliter85742-013e963209c-0b03-4094-8082-9232670fbf5f12025-12-16

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 11 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
81033-01581033-015-16, 81033-015-60
85742-013

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062832-001NYSTATINNYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A062832-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-2784e616aacf4f…
2026-08-18 06:07:402026-07A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-2731067a03dcf5…
2025-08-23 18:47 UTC2025-08A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-276a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-2703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-272680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-275bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-2779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-271e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-278072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-275c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-275d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-274b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-2774a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-2787673890dc5c…
2021-03-12 10:30 UTC2021-03A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-275aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-278869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-273f01610625f2…
2019-09-15 20:21 UTC2019-09A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27b00525d2431f…
2019-07-19 19:46 UTC2019-07A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORAL1991-12-27ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-276a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-271c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-279b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-273f0d92c62455…
2023-05-13 08:27 UTC2023-05A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27053a50430f4f…
2023-01-26 05:58 UTC2023-01A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-273bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-273a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062832-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1991-12-27f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A062832-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A062832-001AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062832-001AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062832-001AA131067a03dcf5…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062832-001AA15bbf6a4d5a75…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062832-001AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062832-001AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062832-001AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062832-001AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062832-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062832-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062832-001AA14b0b4de00fa7…
2022-03-09 01:35 UTC2022-03A062832-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062832-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062832-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A062832-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062832-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062832-001AA1c0c555d07b60…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062832-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062832-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062832-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062832-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062832-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062832-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062832-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A062832-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A062832-001AA13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062832-001AA13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A062832-001AA1f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09A062832-001AA1e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07A062832-001AA1cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A062832-001AA1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 3 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
NYSTATINNYSTATINKesin Pharma Corporation50737729-a4a4-e747-e063-6394a90adcc52026-06-30Adverse reactionsExact identifier
ndc (package): 81033-015-60
ndc (package): 81033-015-16
ndc (product): 81033-015
ndc11 (package): 81033001560
ndc11 (package): 81033001516
spl id: 50738a43-7297-270c-e063-6294a90af2cc
spl set id: 50737729-a4a4-e747-e063-6394a90adcc5
NYSTATINNYSTATINKesin Pharma Corporation43817169-bbe8-58ee-e063-6294a90a12502025-12-11Adverse reactionsExact identifier
ndc (product): 81033-015
NYSTATINNYSTATINKanchan Healthcare Inc90a52c3f-3ef7-4f3b-9fe5-40af408e9f2a2025-09-12Adverse reactionsExact identifier
ndc (product): 85742-013

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.